Drugs / Precemtabart tocentecan
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06806046 | Dec 2024 → Sep 2026 expected | colorectal cancer | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05464030 | Aug 2022 → Oct 2026 expected | colorectal cancer | EMD Serono Research & Development Institute, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06710132 | Jan 2025 → Dec 2027 expected | gastric cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07549412 | May 2026 → Oct 2029 expected | colorectal cancer | EMD Serono Research & Development Institute, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Precemtabart tocentecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549412 ↗ |
| Known as | M9140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05464030 ↗ |
| Known as | Precem-TcT | “Precemtabart tocentecan (Precem-TcT, previously M9140) is an anti-CEACAM5 antibody-drug conjugate with the topoisomerase 1 inhibitor exatecan as payload.” PMID 40739424 ↗ Jul 2025 |
| Modality | Monoclonal antibody | — CHEMBL6068165 ↗ |
| Route | Intravenous | “M9140 intravenously (i.v.)” NCT06710132 ↗ |
| Target | CEACAM5 | “our anti-CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5) specific antibody” PMID 39754485 ↗ Jan 2025 |